PROMIS NEUROSCIENCES INC. Sale of Stock, Consideration Received on Transaction
PROMIS NEUROSCIENCES INC. (PMN) reported Sale of Stock, Consideration Received on Transaction of $27.69 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-03-25
- 2024-09-30: Sale of Stock, Consideration Received on Transaction 9 month $27.69M.
- 2024-07-26: Sale of Stock, Consideration Received on Transaction $27.66M.
- 2023-08-31: Sale of Stock, Consideration Received on Transaction 1 month $9.77M.
| Period end | Sale of Stock, Consideration Received on Transaction | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 9 month |
|---|---|---|---|
| 2024-09-30 | $27.69M 10-Q · filed 2024-11-14 | ||
| 2024-07-26 | $27.66M 10-K · filed 2026-03-25 | ||
| 2023-08-31 | $9.77M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |